news
Boltz-1: A new open-source AI tool for drug discovery
MIT's new open-source AI model, Boltz-1, could transform drug discovery by accurately predicting protein structures, offering global access to researchers.
List view / Grid view
Target Validation
news
New collaboration targets key challenges in fibrosis treatment
Deep Science Ventures and General Inception are teaming up to tackle fibrosis. Together, they aim to create a company focused on developing new treatments for fibrotic diseases.
article
Unleashing the power of AI in target discovery and resilience against disease
In this interview Drug Target Review’s Izzy Wood and Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, uncover the untapped potential of AI in target discovery. Alchemab’s revolutionary platform aims to identify common antibodies in resilient individuals and uncover the antigens that contribute to their disease-fighting…
article
Targeted protein degradation: turning undruggable targets into druggable targets
Targeted protein degradation (TPD) is a cutting-edge approach in drug discovery that offers a more precise and efficient way to alter cellular pathways, offering the capability to convert 'undruggable targets' into 'druggable targets.' In this article, Drug Target Review’s Izzy Wood interviewed Astellas’ Masahiko Hayakawa, Head of Targeted Protein Degradation,…
news
Promising target for osteoporosis treatments found in new study
By identifying a mechanism behind bone strengthening in response to stress, researchers have found a possible new target for treating conditions that weaken bones.
news
Study identifies new therapeutic target for haematologic malignancies
Using chemical genetic screening and pre-clinical model studies, researchers have discovered that inducing ubiquitin-mediated degradation of mutant EZH2 could provide a more effective treatment strategy for haematologic malignancies.
news
Gut-brain pathway metabolite involved in age-related cognitive decline, study shows
In mice, researchers have shown that δ-valerobetaine plays a role in neurocognitive ability, making the metabolite a target for age-related memory loss.
news
Antibody drug target identified for influenza viruses
Researchers have found a small subset of antibodies that target a site at the base of the influenza virus hemagglutinin protein.
article
Target safety assessments – identifying risk early
With an ever-increasing emphasis on minimising drug candidate attrition, scientists are focusing on target safety at earlier points in the research process. In this exclusive interview, Drug Target Review spoke with Dr Gordon Baxter, Chief Scientific Officer of Instem, to learn how target safety assessments can enable researchers to quickly…
article
Improving drug discovery with advanced targeted proteomic monitoring workflows
In this article, Professor Forest White, Department of Biological Engineering at MIT, and Dr Lauren Stopfer, Scientist at BioNTech, present a novel assay approach for the rapid, reproducible and accurate identification of potential therapeutic targets using mass spectrometry.
article
Targeting disease pathways to treat ulcerative colitis – beyond corticosteroid use
Dr Chetan Karyekar, Compound Development Team Leader at The Janssen Pharmaceutical Companies of Johnson & Johnson (J&J), explains how targeting underlying immune pathways can open the door to effectively treating more inflammatory bowel disease (IBD) patients by reducing or eliminating the chronic use of corticosteroids.
news
Scientists uncover mechanisms of potential COVID-19 drug targets
Researchers have used CRISPR and cryogenic electron microscopy to unravel the workings of two receptors involved in diseases such as cancer and COVID-19.
news
NPSR1 gene discovered as a key cause of endometriosis
NPSR1 has been identified as a genetic cause of endometriosis, revealing a potential drug target that may lead to better therapies.
news
Signalling pathway identified as target against paediatric glioma
Researchers have found a vulnerability in a developmental signalling pathway, presenting a target for paediatric low-grade glioma formation.
news
Nanosized molecules inhibit formation of plaques related to Alzheimer’s
In brain tissues, researchers have shown that two different nanosized polyoxoniobate molecules can inhibit the assembly of amyloid plaques.